Loading
Adding radiotherapy before surgery for retroperitoneal sarcoma did not improve abdominal recurrence-free survival overall, so it is no longer routine, though a possible benefit in liposarcoma keeps it under discussion.
Phase 3 trial of 266 patients with primary resectable retroperitoneal sarcoma randomised to preoperative radiotherapy (50.4 Gy) followed by surgery or surgery alone.
Median abdominal recurrence-free survival was 4.5 versus 5.0 years (hazard ratio 1.01), with more serious adverse events in the radiotherapy group; exploratory analysis suggested benefit in well-differentiated and low-grade dedifferentiated liposarcoma but not leiomyosarcoma.
Surgery alone in a reference centre is the standard for primary retroperitoneal sarcoma; preoperative radiotherapy is considered case by case in liposarcoma.
Shares Sylvie Bonvalot, Retroperitoneal sarcoma.
Shares Retroperitoneal sarcoma, Liposarcoma.
Shares Sylvie Bonvalot, The Lancet Oncology.
Shares Retroperitoneal sarcoma, Liposarcoma.
Shares Retroperitoneal sarcoma, Liposarcoma.
Shares STRASS (EORTC 62092), Retroperitoneal sarcoma, Liposarcoma.
Shares Retroperitoneal sarcoma, Liposarcoma.